Child: ≥6 yr 22-31 kg: 600 mg once daily; 32-54 kg: 900 mg once daily; ≥55 kg: 1,200 mg once daily.
Oral Osteoarthritis, Rheumatoid arthritis
Adult: 1,200 mg once daily. Max: 1,800 mg or 26 mg/kg, whichever is lower, given in divided doses.
Special Patient Group
Patient w/ low body wt: Osteoarthritis; Rheumatoid arthritis: Initially, 600 mg once daily.
Osteoarthritis; Rheumatoid arthritis: Severe or on dialysis: Initially, 600 mg once daily, may be increased to 1,200 mg once daily if necessary.
Hypersensitivity. History of bronchospasm, asthma, urticaria, or other allergic-type reactions w/ NSAIDs; active GI bleeding, severe heart failure, recent MI. CABG surgery.
Patient w/ history of peptic ulcer disease and/or GI bleeding, coagulopathy, HTN, oedema, known or risk factors for CV disease, on dialysis, DM, other forms of asthma. Smokers. Severe renal and hepatic impairment. Childn. Pregnancy and lactation.
PO: C (Avoid during 3rd trimester or near delivery), Z (NSAIDs use in >20 weeks gestation may cause oligohydramnios and fetal renal impairment. Fetal ductus arteriosus premature closure and persistent pulmonary hypertension may occur >30 weeks gestation. Avoid NSAIDs 30 weeks and later. If a NSAID is needed during 20-30 weeks, use lowest effective dose for shortest duration.)
Patient Counseling Information
This drug may cause drowsiness, dizziness and blurred vision, if affected, do not drive or operate machinery.
Monitor BP, CBC, K levels, renal function, and LFT. Monitor signs and symptoms of GI bleeding.
Symptoms: Lethargy, drowsiness, nausea, vomiting, abdominal pain, GI bleeding, HTN, acute renal failure, resp depression, coma. Management: Symptomatic and supportive treatment. May consider emesis and/or activated charcoal admin.
Increased risk of renal toxicity w/ diuretics, ACE inhibitors, angiotensin II receptor blockers (ARBs). Increased risk of bleeding w/ anticoagulants, antiplatelets, SSRIs, serotonin norepinephrine reuptake inhibitors. Increased risk of hyperkalaemia w/ ACE inhibitors. May increase serum conc of lithium. May increase serum concentration and prolong the half-life of digoxin. May increase the risk of methotrexate and ciclosporin toxicity. Increased risk of myelosuppression, renal and GI toxicity w/ pemetrexed. May decrease antihypertensive effect of diuretics, ACE inhibitors, ARBs, β-blockers. May decrease natriuretic effect of furosemide. Potentially Fatal: Increased risk of GI adverse events w/ oral corticosteroids, aspirin, anticoagulants, SSRIs.
Increased risk of GI adverse events w/ alcohol.
False positive result for benzodiazepines in urine immunoassay screening test.
Description: Oxaprozin is a propionic acid derivative NSAID w/ analgesic, and antipyretic properties. It inhibits the enzyme cyclooxygenase-1 and 2 (COX-1 and 2) resulting in the blockage of prostaglandin synthesis. Pharmacokinetics: Absorption: Slowly but extensively absorbed from the GI tract. Time to peak plasma concentration: Approx 2-3 hr. Distribution: Volume of distribution: 11-17 L/70 kg. Plasma protein binding: 99%, mainly to albumin. Metabolism: Metabolised in the liver via oxidation and glucuronidation into ester and ether inactive glucuronide metabolites and active phenolic metabolite (small amount). Excretion: Mainly via urine (5%, as unchanged drug; 65%, as metabolites); faeces (35%, as metabolites). Elimination half-life: 41-55 hr.
M01AE12 - oxaprozin ; Belongs to the class of propionic acid derivatives of non-steroidal antiinflammatory and antirheumatic products.
Anon. Oxaprozin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/09/2017.Buckingham R (ed). Oxaprozin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com/. Accessed 19/09/2017.McEvoy GK, Snow EK, Miller J et al (eds). Oxaprozin. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 19/09/2017.Oxaprozin Tablet, Film Coated (PD-Rx Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 19/09/2017.